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mixed treatment comparison (MTC). Triggers for treatment
switches included poor compliance (MTC); lack of IOP control
(MTC); or progression of visual ﬁeld defects (3 long-term clinical
trials). Treatment dropouts were from expert opinion and death
rates from UK national data. Follow-up times are from NHS
treatment pathways, drug costs from UK Drug Tariff December
2007, cost of follow-up visits and surgery from NHS National
Tariff 2007/8, and cost of low vision from a published UK
national study. Utilities were from published sources. RESULTS:
Patients were stable on treatment for 64%, 56%, 55% and 54%
of follow-ups for latanoprost, bimatoprost, travoprost and
timolol respectively. As a result, for every 1000 clinic appoint-
ments, 716 patients can be followed-up for a year if treated with
latanoprost compared to 605 for bitmatoprost (similarly versus
other strategies). The total cost of the latanoprost 1st line strat-
egy is £6165, compared to £6239, £6238 and £6083 for bimato-
prost, travoprost or timolol respectively (including surgery costs
and cost of low vision), with 5.87, 5.85, 5.85 and 5.84 QALYs.
The reduction in time spent with low vision for latanoprost is
approximately 2 months compared to the other strategies. CON-
CLUSIONS: The model demonstrates that stablising a patient on
treatment will lead to reduced disease progression and better
outcomes in the long-term, and other beneﬁts such as more
efﬁcient use of scheduled follow-up visits.
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OBJECTIVES: Unilateral cochlear implantation is generally
accepted as a cost-effective intervention for hearing impaired
patients. They gain understanding in quiet conditions, but report
difﬁculties with sound localization and in noisy conditions. These
can be solved with bilateral implants. Currently in Spain, there
are estimated to be about 350 bilateral cochlear implanted
patients. Our objective is to perform an economic evaluation
of bilateral cochlear implantation in adults and children.
METHODS: We reviewed the published literature to ﬁnd the
effectiveness of bilateral cochlear implantation, and costs of the
intervention, to estimate the incremental cost-effectiveness ratio.
Our model only considers costs for public systems described by
the literature. The time horizon considered is the remaining life
of receipients. We use a discount rate of 3% in future costs and
effects. Conditions under which bilateral cochlear implants could
be cost-effective were explored. RESULTS: In adults we ﬁnd that
bilateral cochlear implantation varies from €53,018/QALY when
intervention is simultaneous up to €63.487/QALY, in the case of
sequential mplantation. In children these ratios show more efﬁ-
ciency, from €44,199 to €56.640/QALY, due to the longer time
they can beneﬁt from implants. CONCLUSIONS: Patients who
already have hearing in one ear can obtain advantages from
Bilateral cochlear implantation. It improves their spatial local-
ization of sound and their hearing in noisy circumstances, but it
has limited impact on quality of life measured as QALYs. Sub-
sequently the incremental cost-effective ratio is higher than
usually accepted in public health systems.
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OBJECTIVES: To characterise the epidemiology and outcome
of people hospitalised with a primary diagnosis of psoriasis has
never been characterised previously in the UK. METHODS:
Routine hospital data from a large geographical area (population
approx. 435,000) were record-linked using probability matching
algorithms to mortality data from the Ofﬁce of National Statis-
tics (1991 to 2005). Relative survival was compared using Cox
proportional hazards models. RESULTS: It was possible to iden-
tify 1935 hospital admissions from 1038 subjects; 49% male.
The mean age at ﬁrst admission was 44 years (sd 20). The
minimum, crude prevalence of people hospitalised with psoriasis
at some time was 0.23%. Coincidentally, these admissions rep-
resented 0.23% of all hospital admissions. The crude admission
rate with a primary diagnosis of psoriasis was 2.9 per 10,000
population per year. The proportion of subjects who had only
one admission ranged between 65% and 77%. The median time
between the ﬁrst admission and the second admission was 1.4
years (IQR 0.5 to 3.1). The mean length of hospital stay was 16.8
days (median 15; IQR 8 to 23). There were 55 deaths in total in
this group. Ten year survival was between 94% and 95%. Fol-
lowing standardisation, people admitted more than once had
increased risk of all cause mortality (hazard ratio 2.71; 95% CI
1.39 to 5.31). CONCLUSIONS: This study provides useful back-
ground intelligence on the most severe psoriasis patients. The
proportion of psoriasis patients admitted was estimated to be
about one in six people. Those with more than one admission
with psoriasis—greater psoriasis severity—were associated with
increased risk of all-cause mortality.
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OBJECTIVES: To identify non compliant glaucoma patients
with the EDSQ, the Eye Drop Satisfaction Questionnaire.
METHODS: Patients were treated for glaucoma or ocular hyper-
tension with either Travatan® or DuoTrav®. Non compliant
patients were identiﬁed with a computerized device (Travalert®)
that collects daily instillation time and number of drops. The
EDSQ was completed once patients used the device for 3 months.
EDSQ included six domains: Concern about treatment, Concern
about disease, Satisfaction with patient-clinician relationship,
Positive beliefs, Treatment convenience, and Declared compli-
ance. Non compliant patients were over-sampled to reach a ratio
1 complier: 1 non complier. A Bayesian network was constructed
to identify non compliers. The “Taboo order” algorithm was
used to estimate associations. Missing data were inferred accord-
ing to the EM structural method. EDSQ scores were dichoto-
mised according to a decision tree aimed at maximising non
complier identiﬁcation. RESULTS: Among the 176 patients who
completed EDSQ, 113 patients used adequately Travalert®. 25
(22.1%) patients were identiﬁed as non complier. No difference
between compliers and non compliers were found on demo-
graphics and baseline medical data. The 6 EDSQ dimensions
were found to be associated directly or indirectly with compli-
ance. The Bayesian network identiﬁed 3 populations whose a
posteriori probabilities were different from a priori. Patients
declaring low compliance, aged <77.5, with a poor patient-
clinician relationship and patients declaring good compliance,
aged >77.5, with a poor patient-clinician relationship were at
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high risk to be non compliant. Patients declaring good compli-
ance, aged <77.5, with a good patient-clinician relationship were
likely to be compliant. CONCLUSIONS: When medical data
were not associated with compliance, patient reported outcome
might help at identifying glaucoma treatment compliance issues.
Treatment compliance is a complex concept, including several
dimensions with interactions. EDSQ demonstrated some abilities
at identifying non compliant patients. Age, declared compliance
and satisfaction with patient-clinician relationship are dimen-
sions that would be worth being explored before switching a
glaucoma treatment due to lack of intra-ocular pressure control.
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OBJECTIVES: It has long been suspected that treatment compli-
ance is affected by HRQoL. The aim of this study is to assess how
compliance is related to GSS scores and other treatment variables
in Glaucoma. METHODS: An observational study was carried
out gathering information on the Spanish version of the Glau-
coma Symptom Scale (GSS), three compliance scales (Morisky-
Green, Haynes-Sackett, & Batalla) and information about
disease severity and treatment. Concordance between adherence
scales was ﬁrst assessed. Using the Morisky-Green score as target
criteria, a segmentation tree was tested in order to forecast
compliance probability. CHAID growing algorithm was used.
RESULTS: A sample of 367 patients was recruited with an
average age of 68 (12.1) years from which 57% were females.
Most patients (87.7%) were diagnosed of glaucoma, 10.5% were
diagnosed of glaucoma and severe PIO and 1.8% presented sever
PIO alone. Agreement between adherence scales was poor with
a marked superiority of the Morisky-Green questionnaire. The
most signiﬁcant segmentation variable was GSS score, followed
by age, glaucoma severity (as assessed by the clinician), number
of treatment drugs, and number treatment of drops. Interaction
was found between number of drops and other variables in the
model. CONCLUSIONS: Using the tree model developed it is
possible to predict compliance probability. Self perceived sym-
ptom discomfort is found to be the best predictor. Additional
evidences of GSS construct validity as a measure of HRQoL have
been found.
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OBJECTIVES: To assess the effect of moderate to severe psoriasis
on quality of life (QoL) in Spanish patients. METHODS: An
observational study was conducted at 132 centers in Spain which
included 10 consecutive patients with moderate to severe psoria-
sis, deﬁned as: 1) patients with Body Surface Area >= 10 or 2)
Psoriasis Area and Severity Index (PASI) >= 10 or 3) Physician’s
Global Assessment >= 5 or 4) patients receiving systemic treat-
ment. Demographic data, medical history, treatments, occupa-
tional impairment, current state of the disease, resource use, and
QoL using the Dermatology Life Quality Index (DLQI) and other
questionnaires were collected. The DLQI is a self-administered
questionnaire with 10 questions measuring 6 domains: symp-
toms and feelings, daily activities, leisure, work and school,
personal relationships and treatment. DLQI results are shown as
mean scores and percentages (mean value obtained over the
maximum score of the domain). RESULTS: A total of 1307
(1141 with complete data) patients with moderate to severe
psoriasis fulﬁlled the inclusion criteria for the present study (38%
female), with a mean age of 45.7  0.9 (mean  SD) years, mean
duration of the disease of 23.3  2.3 years and mean PASI score
of 13.1  0.3. The mean DLQI score was 8.7  0.2, meaning a
moderate effect of psoriasis on patient life. Highest mean scores
(worst) were obtained in symptoms and feelings (2.7, 45%) and
treatment (1.0, 33%) domains and lowest mean scores were
obtained in personal relationships (1.1, 18%) and work and
school (0.7, 23%) domains. Mean scores for daily activities and
leisure were 1.7 (28%) and 1.6 (26%) respectively. CONCLU-
SIONS: Moderate to severe psoriasis has a negative impact on
patient QoL. A more intensive and integrated approach to these
patients should be considered to achieve a smaller impact of
psoriasis on patients’ quality of life.
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OBJECTIVES: To conﬁrm the reliability of quality-of-life (QOL)
assessments in a randomized controlled trial (RCT), we investi-
gated the changes in internal standards as a representative of
‘response shift (RS)’. METHODS: One-hundred and three
patients with age-related maculopathy in Japan were randomized
to the intervention group and the control group. The intervention
group received a standardized low vision care program for 6
months. For ethical considerations, low vision care was also
provided for applicants in the control group after 6 months. We
assessed visual function-related QOL using the Japanese version
of the 25-item National Eye Institute Visual Function Question-
naire (VFQ-25) at baseline, 6-, and 12-months. We asked the
patients to answer an additional questionnaire to investigate the
changes in internal standards at 6- and 12- months which
inquired about QOL at baseline (then-test). This questionnaire
included 7 items selected from the VFQ-25 as the representatives
of major 7 domains (general vision [GV], near vision [NV],
distance vision [DV], social function [SF], mental health [MH],
role limitations [RL], and dependency [DP]). RESULTS: Fifty-
four patients at 6-months and 52 patients at 12-months com-
pleted the then-test questionnaire in addition to the VFQ-25.
Regardless of the direction of change (improved or deteriorated)
in scores, the then-test results tended to decrease the difference
of the scores. That is, then-test scores tended to be higher than
baseline scores in the case of improvement, and tended to be
lower than baseline scores in the case of deterioration. The
statistically signiﬁcant difference was observed between pre- and
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